CAS: 461-78-9; 1-(4-Chlorophenyl)-2-Methylpropan-2-Amine
- 英文名称1-(4-Chlorophenyl)-2-Methylpropan-2-Amine
- 中文名称对氯苯丁胺
- IUPAC名称1-(4-chlorophenyl)-2-methylpropan-2-amine
- 其它别名Phenethylamine,p-chloro-a,a-dimethyl- (6CI,8CI); 1-(4-Chlorophenyl)-2-methylpropan-2-amine; 1-(p-Chlorophenyl)-2-methyl-2-aminopropane; 4-Chloro-a,a-dimethylphenethylamine; Chlorphentermine; Clorfentermina; Desopimon; Effox; Lucofen SA; Teramine; p-Chloro-a,a-dimethylphenethylamine; a,a-Dimethyl-4-chlorobenzeneethanamine
- CAS编号461-78-9
- MFCD编号:MFCD00055368
- EINECS号:207-314-9
- FDA UNII编号:NHW07912O7
- 分子式:C10H14ClN分子量:183.68
- 产品CID: 1461484
- 产品分类原料药 → 消化系统用药 → 食欲抑制药及其它减肥药
物理性质
MSDS等安全信息
- GHS象形图
- GHS符号GHS07;
注释: Exclamation mark - 危险类别急性毒性 类别4(经口)
特定目标器官毒性 - 单次接触 类别3
皮肤腐蚀/刺激 类别2
严重眼刺激 类别2 - 警示词Warning(警告)
- 危险描述H302 |吞咽有害.
H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激. - 防范说明P264-P280-P305+P351+P338-P337+P313P-P264-P280-P302+P352-P321-P332+P313-P362-P264-P270-P301+P312-P330-P501
- 危险等级IRRITANT
- 安全声明IDENTIFICATION: Chlorphentermine hydrochloride is a centrally acting antiobesity drug. HUMAN EXPOSURE: Main risks and target organs: Acute central nervous system stimulation, cardiotoxicity causing tachycardia, arrhythmias, hypertension and cardiovascular collapse. High risk of dependency and abuse. Summary of clinical effects: Cardiovascular: Palpitation, chest pain, tachycardia, arrhythmias and hypertension are common; cardiovascular collapse can occur in severe poisoning. Myocardial ischemia, infarction and ventricular dysfunction are described. Central Nervous System (CNS): Stimulation of CNS, tremor, restlessness, agitation, insomnia, increased motor activity, headache, convulsions, coma and hyperreflexia are described. Stroke and cerebral vasculitis have been observed. Gastrointestinal: Vomiting, diarrhea and cramps may occur. Genitourinary: Increased bladder sphincter tone may cause dysuria, hesitancy and acute urinary retention. Renal failure can occurs secondary to dehydration or rhabdomyolysis. Renal ischemia may be noted. Dermatologic: Skin is usually pale and diaphoretic, but mucous membranes appear dry. Endocrine: Transient hyperthyroxinemia may be noted. Metabolism: Increased metabolic and muscular activity may result in hyperventilation and hyperthermia. Weight loss is common with chronic use. Fluid/Electrolyte: Hypo- and hyperkalemia have been reported. Dehydration is common. Musculoskeletal: Fasciculations and rigidity may be noted. Rhabdomyolysis is an important consequence of severe amphetamine poisoning. Psychiatric: Agitation, confusion, mood elevation, increased wakefulness, talkativeness, irritability and panic attacks are Tourette syndrome and other disorders, hyperthyroidism, narrow angle glaucoma typical. Chronic abuse can cause delusions and paranoia. A withdrawal syndrome occurs after abrupt cessation following chronic use. Contraindications: Anorexia, insomnia, psychopathic personality disorders, suicidal tendencies, diabetes mellitius and cardiovascular diseases such as angina, hypertension and arrythmias. Routes of exposure: Oral: Readily absorbed from the gastro-intestinal tract and buccal mucosa. It is resistant to metabolism by monoamine oxidase. Inhalation: Amphetamine is rapidly absorbed by inhalation and is often abused by this route. Parenteral: Frequent route of entry in abuse situations. Absorption by route of exposure: Amphetamine is rapidly absorbed after oral ingestion. Peak plasma levels occur within 1 to 3 hours, varying with the degree of physical activity and the amount of food in the stomach. Absorption is usually complete by 4 to 6 hours. Sustained release preparations are available as resin-bound, rather than soluble, salts. These compounds display reduced peak blood levels compared with standard amphetamine preparations, but total amount absorbed and time to peak levels remain similar. Distribution by route of exposure: Amphetamines are concentrated in the kidney, lungs, cerebrospinal fluid and brain. They are highly lipid soluble and readily cross the blood-brain barrier. Biological half-life by route of exposure: Under normal conditions, about 30% of amphetamine is excreted unchanged in the urine but this excretion is highly variable and is dependent on urinary pH. When the urinary pH is acidic (pH 5.5 to 6.0), elimination is predominantly by urinary excretion with approximately 60% of a dose of amphetamine being excreted unchanged by the kidney within 48 hours. When the urinary pH is alkaline (pH 7.5 to 8.0), elimination is predominantly by deamination (less than 7% excreted unchanged in the urine); the half-life ranging from 16 to 31 hours. Metabolism: The major metabolic pathway for amphetamine involves deamination by cytochrome P450 to para-hydroxyamphetamine and phenylacetone; this latter compound is subsequently oxidized to benzoic acid and excreted as glucuronide or glycine (hippuric acid) conjugate. Smaller amounts of amphetamine are converted to norephedrine by oxidation. Hydroxylation produces an active metabolite, O-hydroxynorephedrine, which acts as a false neurotransmitter and may account for some drug effect, especially in chronic users. Elimination and excretion: Normally 5 to 30% of a therapeutic dose of amphetamine is excreted unchanged in the urine by 24 hours, but the actual amount of urinary excretion and metabolism is highly pH dependent. Mode of action: Amphetamine appears to exert most or all of its effect in the CNS by causing release of biogenic amines, especialy norepinephrine and dopamine, from storage sites in nerve terminals. It may also slow down catecholamine metabolism by inhibiting monoamine oxidase. Teratogenicity: The use of amphetamine for medical indications does not pose a significant risk to the fetus for congenital anomalies. Amphetamines generally do not appear to be human teratogens. Mild withdrawal symptoms may be observed in the newborn, but the few studies of infant follow-up have not shown long-term sequelae, although more studies of this nature are needed. Illicit maternal use or abuse of amphetamine presents a significant risk to the fetus and newborn, including intrauterine growth retardation, premature delivery and the potential for increased maternal, fetal and neonatal morbidity. These poor outcomes are probably multifactorial in origin, involving multiple drug use, life-styles and poor maternal health. However, cerebral injuries occurring in newborns exposed in utero appear to be directly related to the vasoconstrictive properties of amphetamines. Sixty-five were followed children whose mothers were addicted to amphetamine during pregnancy, at least during the first trimester. Intelligence, psychological function, growth, and physical health were all within the normal range at eight years, but those children exposed throughout pregnancy tended to be more aggressive. Interactions: Acetazolamide: administration may increase serum concentration of amphetamine. Alcohol: may increase serum concentration of amphetamine. Ascorbic acid: lowering urinary pH, may enhance amphetamine excretion. Furazolidone: amphetamines may induce a hypertensive response in patients taking furazolidone. Guanethidine: amphetamine inhibits the antihypertensive response to guanethidine. Haloperidol: limited evidence indicates that haloperidol may inhibit the effects of amphetamine but the clinical importance of this interaction is not established. Lithium carbonate: isolated case reports indicate that lithium may inhibit the effects of amphetamine. Monoamine oxidase inhibitor: severe hypertensive reactions have followed the administration of amphetamines to patients taking monoamine oxidase inhibitors. Norepinephrine: amphetamine abuse may enhance the pressor response to noradrenaline. Phenothiazines: amphetamine may inhibit the antipsychotic effect of phenothiazines, and phenothiazines may inhibit the anorectic effect of amphetamines. Sodium bicarbonate: large doses of sodium bicarbonate inhibit the elimination of amphetamine, thus increasing the amphetamine effect. Tricyclic antidepressants: theoretically increases the effect of amphetamine, but clinical evidence is lacking. /Chlorphentermine hydrochloride/
欧盟法规
ECHA物质C&L通报REACH预注册上下游产品
CAS号5468-97-3 1-(4-氯苯基)-2-甲基-2-丙醇 | CAS号78558-98-2 N-[1-(4-chlorop... | CAS号104-83-6 4-氯氯苄 | CAS号52449-43-1 4-氯苯乙酸甲酯 | CAS号17743-62-3 N-(2-(4-Chlorop... | CAS号89516-34-7 1-(2-acetylphen... | CAS号5531-31-7 α,α-Dimethylcyc...合成工艺路线路线简述
📜1-(4-氯苯基)-2-甲基-2-丙醇置于盐酸,硫酸,水,溶剂黄146体系中,用 1,4-二氧六环 作为反应溶剂,化学反应 16.0H,反应生成 对氯苯丁胺
参考文献:(Alpha-Substituted Aralkylamino And Heteroarylalkylamino) Pyrimidinyl And 1,3,5-Triazinyl Benzimidazoles,Pharmaceutical Compositions Thereof,And Their Use In Treating Proliferative Diseases
标题:(Alpha-Substituted Aralkylamino And Heteroarylalkylamino) Pyrimidinyl And 1,3,5-Triazinyl Benzimidazoles,Pharmaceutical Compositions Thereof,And Their Use In Treating Proliferative Diseases
摘要:本文提供了(α-取代的芳基氨基或杂环芳基氨基)嘧啶基和1,3,5-三嗪基苯并咪唑类化合物,例如,式i的化合物,以及它们的药物组合物,制备方法,以及作为治疗增殖性疾病的药剂或药物的用途.
海关参考信息
- 2902600000-乙苯
2903919090-氯苯
2903991000-对氯甲苯 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-11717498-B2
优先权日:2013-12-31
标题 :Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms
发明人：POPP KARL; MECKLER HAROLD
权利人:Chemapotheca LLC; PHARMAPOTHECA A INC
摘要:The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.
专利号:US-8598153-B2
优先权日:2006-09-22
标题 :Method of treatment using fatty acid synthesis inhibitors
发明人：SINGH SHEO B; TOTA MICHAEL R; WANG JUN
权利人:SINGH SHEO B; TOTA MICHAEL R; WANG JUN; MERCK SHARP & DOHME
摘要:The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.
专利号:US-10968192-B2
优先权日:2018-09-26
标题:Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis
发明人：BEDNARZ MARK STEPHEN; Dai Kuangchu; ECKERT JEFFREY MANNING; LIM NGIAP-KIE; SIROIS LAUREN; WU WENXUE; ZHAO MATTHEW MANGZHU
权利人:LEXICON PHARMACEUTICALS INC
摘要:Methods of preparing, and solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide, and salts, solvates and cocrystals thereof, are disclosed.
专利号:US-7078406-B2
优先权日:2001-10-09
标 题 :Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
发明人：CARVER JR THEODORE E; RINKER JAMES M
权利人:JOHNSON & JOHNSON PHARM RES
摘要:The present invention is directed to a compound of Formula I: n nwherein A, R 1 , and R 2 are defined herein. The present invention is also directed to compositions comprising compounds of Formula I, methods of using compounds of Formula I, and methods of making compounds of Formula I.
专利号:US-6277489-B1
优先权日:1998-12-04
标题:Support for high performance affinity chromatography and other uses
发明人：ABBOTT NICHOLAS; STROEVE PIETER; DUBROVSKY TIMOTHY B; HOU ZHIZHONG
权利人:UNIV CALIFORNIA
摘要:Multilayered particulate materials are formed by coating a particulate substrate with a metal and adsorbing an organic layer comprising a recognition moiety onto the metal film. The recognition moiety interacts with an analyte of interest allowing for its detection, purification, etc. Suitable recognition moieties can be selected from a range of species including, small molecules, polymers and biomolecules and the like. The novel particulate materials of the invention can be utilized in an array of methods including, ion-exchange, ion-selective ion-exchange, assays, affinity dialysis, size exclusion dialysis, as supports in solid phase synthesis, combinatorial synthesis and screening of compound libraries and the like.
专利号:US-2020255394-A1
优先权日:2018-09-26
标题 :Crystalline solid forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
摘要:Acta Poloniae Pharmaceutica, 26(598), 1969
摘要:
摘要:International Programme on Chemical Safety; Poisons Information Monograph: Chlorphentermine Hydrochloride (PIM 935) (1998) Available from, as of October 24, 2005:
摘要:American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 489
摘要:American Medical Association. AMA Drug Evaluations Annual 1991. Chicago, IL: American Medical Association, 1991., p. 1997
📝 需求与反馈
尽可能描述清楚需求与问题信息
